Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study

Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study

Background: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectivel...

Full description

Bibliographic Details
Main Authors: Tomomichi Iizuka, Kozo Morimoto, Yuka Sasaki, Masashi Kameyama, Atsuyuki Kurashima, Kazumasa Hayasaka, Hideo Ogata, Hajime Goto
Format: Article
Language:English
Published: Karger Publishers 2017-06-01
Series:Dementia and Geriatric Cognitive Disorders Extra
Subjects:
Preventive therapy
Alzheimer disease
FDG-PET
Rifampicin
Amyloid-β
Oligomer
Online Access:http://www.karger.com/Article/FullText/477343

Similar Items

Similar Items